Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, has entered into multi-year strategic agreements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the company’s next version of core technology, Electrotransfection System.
Financial terms of the agreement were not disclosed by the company.
Electrotransfection System is a non-viral gene therapy ocular drug delivery platform designed to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle and sustainably treat major eye diseases. This technology enables the eye to generate its own therapeutic proteins.
The company is now working to develop a new generation system devices specialized in optimizing their ease-of-use and manufacturability.
Works at both contracts have already begun, with Phillips-Medisize working on optimization and the high-volume manufacturing capability to support the commercial launch for Ocular Devices. On the other hand, Minnetronix Medical will undertake the same responsibilities for the Pulse Generator component.
“The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess," Alan Wirbisky, Director of Device Development at Eyevensys, said in a company news release.
Benjamin Austin, Director of Business Development at Minnetronix Medical, said: “We are beyond excited to partner with Eyevensys to help bring their next-generation Pulse Generator to market. During our 25 year history, we have successfully partnered with many medical startups like Eyevenesys to navigate the pitfalls of electromechanical medical device development.”
Founded in 2008, Eyevensys is a privately held, clinical-stage biotechnology company developing its innovative technology to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic diseases.
The company has offices in France and the U.S., and receives funding from Boehringer Ingelheim Venture Fund, Pureos Bioventures, Bpifrance through the Innobio Fund, Karista, Inserm Transfert Initiative, Pontifax and the Global Health Sciences Fund, Korean Investment Partners.